Thitiya Dejthevaporn
Overview
Explore the profile of Thitiya Dejthevaporn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
31
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iemwimangsa N, Anantaya D, Oranratnachai S, Thamrongjirapat T, Lumjiaktase P, Teoh V, et al.
BMC Cancer
. 2025 Feb;
25(1):333.
PMID: 39994571
Background: One-year of immune checkpoint inhibitor (ICI) treatment after concurrent chemoradiation (CCRT) in unresectable stage III non-small cell lung cancer (NSCLC) is a standard of care. The precise predictive biomarkers...
2.
Dajsakdipon T, Pipatsakulroj W, Dejthevaporn T
JCO Glob Oncol
. 2024 Sep;
10:e2400132.
PMID: 39265132
Purpose: Breast cancer progression varies across molecular subtypes, and treatment options for human epidermal growth factor receptor 2 (HER2)-low expression tumors are limited compared with those of HER2 overexpression tumors....
3.
Dajsakdipon T, Susiriwatananont T, Wongkraisri C, Ithimakin S, Parinyanitikul N, Supavavej A, et al.
BMC Cancer
. 2024 Aug;
24(1):1018.
PMID: 39152401
Background: The current standard first-line treatment for hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR + /HER2 -) advanced breast cancer (ABC) is a combination of aromatase inhibitor (AI)...
4.
Gunasekara A, Youngkong S, Anothaisintawee T, Dejthevaporn T, Fernandopulle R, Chaikledkaew U
Sci Rep
. 2024 Jul;
14(1):16736.
PMID: 39033229
This study aimed to assess the cost-utility and budget impact of dual to single HER2 targeted neoadjuvant therapy for HER2-positive breast cancer in Sri Lanka. A five-health state Markov model...
5.
Dejthevaporn T, Patanayindee P
Breast Cancer (Auckl)
. 2023 Aug;
17:11782234231186869.
PMID: 37533837
Background: The risk of late distant recurrence (LDR) of estrogen receptor (ER)-positive breast cancer continues even after 5 years of endocrine treatment. Clinical Treatment Score after 5 years (CTS5) was...
6.
Khiewngam K, Oranratnachai S, Kamprerasart K, Kunakorntham P, Sanvarinda P, Trachu N, et al.
Front Oncol
. 2023 Mar;
13:1047644.
PMID: 36895484
Background: Despite significant benefits of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment in patients with -mutated NSCLC, access remains limited in Thailand and elsewhere. Methods: Retrospective analysis of patients...
7.
Ithimakin S, Parinyanitikul N, Kim S, Yap Y, Tsang J, Soong I, et al.
J Breast Cancer
. 2022 Jun;
25(3):207-217.
PMID: 35657002
Purpose: Breast cancer (BC) treatment has shifted from chemotherapy to targeted therapy. Several targeted agents have demonstrated an improvement in survival. Given that national healthcare resources were correlated with the...
8.
Dajsakdipon T, Siripoon T, Ngamphaiboon N, Ativitavas T, Dejthevaporn T
Curr Treat Options Oncol
. 2022 Mar;
23(3):415-438.
PMID: 35262852
Sarcoma describes a rare and heterogeneous group of diseases. Current treatment options for metastatic sarcoma are quite limited. Conventional treatments with chemotherapy or anti-angiogenic agents result in a non-durable response...
9.
Schutz F, Sirachainan E, Kuppusamy S, Hoa N, Dejthevaporn T, Bahadzor B, et al.
Ther Adv Med Oncol
. 2021 Mar;
13:1758835920985464.
PMID: 33747148
Aims: Clinical decision making is challenging in men with metastatic prostate cancer (mPC), as heterogeneity in treatment options and patient characteristics have resulted in multiple scenarios with little or no...
10.
Chibaudel B, Henriques J, Rakez M, Brenner B, Kim T, Martinez-Villacampa M, et al.
JAMA Netw Open
. 2020 Oct;
3(10):e2020425.
PMID: 33074326
Importance: In the pivotal Bevacizumab-Avastin Adjuvant (AVANT) trial, patients with high-risk stage II colon cancer (CC) had 5-year and 10-year overall survival (OS) rates of 88% and 75%, respectively, with...